These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 19439100)

  • 1. Metabolically stable bradykinin B2 receptor agonists enhance transvascular drug delivery into malignant brain tumors by increasing drug half-life.
    Sarin H; Kanevsky AS; Fung SH; Butman JA; Cox RW; Glen D; Reynolds R; Auh S
    J Transl Med; 2009 May; 7():33. PubMed ID: 19439100
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Physiologic upper limit of pore size in the blood-tumor barrier of malignant solid tumors.
    Sarin H; Kanevsky AS; Wu H; Sousa AA; Wilson CM; Aronova MA; Griffiths GL; Leapman RD; Vo HQ
    J Transl Med; 2009 Jun; 7():51. PubMed ID: 19549317
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The development of the bradykinin agonist labradimil as a means to increase the permeability of the blood-brain barrier: from concept to clinical evaluation.
    Emerich DF; Dean RL; Osborn C; Bartus RT
    Clin Pharmacokinet; 2001; 40(2):105-23. PubMed ID: 11286321
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dual kinin B1 and B2 receptor activation provides enhanced blood-brain barrier permeability and anticancer drug delivery into brain tumors.
    Côté J; Savard M; Neugebauer W; Fortin D; Lepage M; Gobeil F
    Cancer Biol Ther; 2013 Sep; 14(9):806-11. PubMed ID: 23792591
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Selective tumor blood-brain barrier opening with the kinin B2 receptor agonist [Phe(8)psi(CH(2)NH)Arg(9)]-BK in a F98 glioma rat model: an MRI study.
    Côté J; Savard M; Bovenzi V; Dubuc C; Tremblay L; Tsanaclis AM; Fortin D; Lepage M; Gobeil F
    Neuropeptides; 2010 Apr; 44(2):177-85. PubMed ID: 20080302
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhanced tumor uptake of carboplatin and survival in glioma-bearing rats by intracarotid infusion of bradykinin analog, RMP-7.
    Matsukado K; Inamura T; Nakano S; Fukui M; Bartus RT; Black KL
    Neurosurgery; 1996 Jul; 39(1):125-33; discussion 133-4. PubMed ID: 8805148
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effective transvascular delivery of nanoparticles across the blood-brain tumor barrier into malignant glioma cells.
    Sarin H; Kanevsky AS; Wu H; Brimacombe KR; Fung SH; Sousa AA; Auh S; Wilson CM; Sharma K; Aronova MA; Leapman RD; Griffiths GL; Hall MD
    J Transl Med; 2008 Dec; 6():80. PubMed ID: 19094226
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evidence that Cereport's ability to increase permeability of rat gliomas is dependent upon extent of tumor growth: implications for treating newly emerging tumor colonies.
    Bartus RT; Snodgrass P; Dean RL; Kordower JH; Emerich DF
    Exp Neurol; 2000 Jan; 161(1):234-44. PubMed ID: 10683290
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bradykinin modulation of tumor vasculature: I. Activation of B2 receptors increases delivery of chemotherapeutic agents into solid peripheral tumors, enhancing their efficacy.
    Emerich DF; Snodgrass P; Dean RL; Lafreniere D; Agostino M; Wiens T; Xiong H; Hasler B; Marsh J; Pink M; Kim BS; Bartus RT
    J Pharmacol Exp Ther; 2001 Feb; 296(2):623-31. PubMed ID: 11160651
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enhanced delivery of carboplatin into brain tumours with intravenous Cereport (RMP-7): dramatic differences and insight gained from dosing parameters.
    Emerich DF; Snodgrass P; Dean R; Agostino M; Hasler B; Pink M; Xiong H; Kim BS; Bartus RT
    Br J Cancer; 1999 Jun; 80(7):964-70. PubMed ID: 10362103
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cereport (RMP-7) increases carboplatin levels in brain tumors after pretreatment with dexamethasone.
    Dean RL; Emerich DF; Hasler BP; Bartus RT
    Neuro Oncol; 1999 Oct; 1(4):268-74. PubMed ID: 11550318
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of permeability, doxorubicin delivery, and drug retention in a rat brain tumor model after ultrasound-induced blood-tumor barrier disruption.
    Park J; Aryal M; Vykhodtseva N; Zhang YZ; McDannold N
    J Control Release; 2017 Mar; 250():77-85. PubMed ID: 27742444
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Repeated, short-term ischemia augments bradykinin-mediated opening of the blood-tumor barrier in rats with RG2 glioma.
    Liu Y; Hashizume K; Samoto K; Sugita M; Ningaraj N; Asotra K; Black KL
    Neurol Res; 2001 Sep; 23(6):631-40. PubMed ID: 11547933
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Unlocking the blood-brain barrier: a role for RMP-7 in brain tumor therapy.
    Elliott PJ; Hayward NJ; Huff MR; Nagle TL; Black KL; Bartus RT
    Exp Neurol; 1996 Oct; 141(2):214-24. PubMed ID: 8812155
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Selective opening of the blood-tumor barrier by a nitric oxide donor and long-term survival in rats with C6 gliomas.
    Weyerbrock A; Walbridge S; Pluta RM; Saavedra JE; Keefer LK; Oldfield EH
    J Neurosurg; 2003 Oct; 99(4):728-37. PubMed ID: 14567609
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Overcoming the blood-brain tumor barrier for effective glioblastoma treatment.
    van Tellingen O; Yetkin-Arik B; de Gooijer MC; Wesseling P; Wurdinger T; de Vries HE
    Drug Resist Updat; 2015 Mar; 19():1-12. PubMed ID: 25791797
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bradykinin modulation of tumor vasculature: II. activation of nitric oxide and phospholipase A2/prostaglandin signaling pathways synergistically modifies vascular physiology and morphology to enhance delivery of chemotherapeutic agents to tumors.
    Emerich DF; Dean RL; Snodgrass P; Lafreniere D; Agostino M; Wiens T; Xiong H; Hasler B; Marsh J; Pink M; Kim BS; Perdomo B; Bartus RT
    J Pharmacol Exp Ther; 2001 Feb; 296(2):632-41. PubMed ID: 11160652
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Retro-inverso bradykinin opens the door of blood-brain tumor barrier for nanocarriers in glioma treatment.
    Xie Z; Shen Q; Xie C; Lu W; Peng C; Wei X; Li X; Su B; Gao C; Liu M
    Cancer Lett; 2015 Dec; 369(1):144-51. PubMed ID: 26282786
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enhancement in blood-tumor barrier permeability and delivery of liposomal doxorubicin using focused ultrasound and microbubbles: evaluation during tumor progression in a rat glioma model.
    Aryal M; Park J; Vykhodtseva N; Zhang YZ; McDannold N
    Phys Med Biol; 2015 Mar; 60(6):2511-27. PubMed ID: 25746014
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Induction of selective blood-tumor barrier permeability and macromolecular transport by a biostable kinin B1 receptor agonist in a glioma rat model.
    Côté J; Bovenzi V; Savard M; Dubuc C; Fortier A; Neugebauer W; Tremblay L; Müller-Esterl W; Tsanaclis AM; Lepage M; Fortin D; Gobeil F
    PLoS One; 2012; 7(5):e37485. PubMed ID: 22629405
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.